Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576–586)
Year: 2021
Type: letter
Source: Ophthalmology
Author: Tiarnan D.L. Keenan
Institutions: National Institutes of Health, National Eye Institute
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3126900178